Annals of Epidemiology
Volume 15, Issue 3 , Pages 202-206 , March 2005

Prevalence of the Metabolic Syndrome in Relation to Self-reported Cancer History

Received 6 April 2004 ,Accepted 22 July 2004.

References 

  1. Laaksonen DE, Lakka HM, Salonen JT, Niskanen LK, Rauramaa R, Lakka TA. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome. Diabetes Care. 2002;25:1612–1618
  2. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes. 2002;51:3120–3127
  3. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 2002;25:1790–1794
  4. Onat A, Ceyhan K, Sansoy V, Basar O, Erer B, Uysal O, et al. Fasting insulin levels independently associated with coronary heart disease in non-diabetic Turkish men and women. Int J Cardiol. 2002;86:61–69
  5. Reusch JE. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol. 2002;90:19G–26G
  6. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: A population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol. 1998;148:958–966
  7. Jia WP, Xiang KS, Chen L, Lu JX, Wu YM. Epidemiological study on obesity and its comorbidities in urban Chinese older than 20 years of age in Shanghai, China. Obes Rev. 2002;3:157–165
  8. Oldridge NB, Stump TE, Nothwehr FK, Clark DO. Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults. J Clin Epidemiol. 2001;54:928–934
  9. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69–75
  10. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  11. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998;98:398–404
  12. Salomaa V, Riley W, Kark JD, Nardo C, Folsom AR. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation. 1995;91:1432–1443
  13. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care. 1991;14:461–469
  14. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–980
  15. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979;2:154–160
  16. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2002. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm. Accessed March 25, 2004.
  17. Marks V. The metabolic syndrome. Nursing Standard. 2003;17:37–44
  18. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: Prevalence and associated risk factors in the US population from the Third National Health and Nutrition Examination Survey, 1998-1994. Arch Intern Med. 2003;163:427–436
  19. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  20. Talvensaari KK, Lanning M, Tapanainen P, Knip M. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab. 1996;81:3051–3055
  21. Birkebaek NH, Clausen N. Height and weight pattern up to 20 years after treatment for acute lymphoblastic leukaemia. Arch Dis Child. 1998;79:161–164
  22. Talvensaari K, Knip M. Childhood cancer and later development of the metabolic syndrome. Ann Med. 1997;29:353–355
  23. Nuver J, Smit AJ, Postma A, Sleijfer DT, Gietema JA. The metabolic syndrome in long-term cancer survivors: An important target for secondary preventive measures. Cancer Treat Rev. 2002;28:195–214
  24. Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atheroscelrosis in long-term survivors of disseminated testicular cancer. Eur J Cancer. 2004;40:701–706
  25. Singara D, Amato C, Scarpitta AM, Brigandi M, Amato M, Saura G, et al. Metabolic syndrome and breast cancer risk. Eur Rev Med Pharmacol Sci. 2002;6:55–59
  26. Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG. Relationships between tomoxifen use, liver fat, and body fat distribution in women with breast cancer. Int J Obesity. 2001;25:296–298
  27. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–1743
  28. Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997;15:61–68
  29. Matthys D, Verhaaren H, Benoit Y, Laureys G, De Naeyer A, Craen M. Gender difference in aerobic capacity in adolescents after cure from malignant disease in childhood. Acta Paediatr. 1993;82:459–462
  30. Colvin M, Hilton J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rep. 1981;65(suppl. 3):89–95
  31. Erselcan T, Kairemo KJ, Wiklund TA, Hernberg M, Blomqvist CP, Tenhunen M, et al. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer. Br J Cancer. 2000;82:777–781
  32. Morandi P, Ruffini PA, Benvenuto GM, La Vecchia L, Mezzena G, Raimondi R. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide. Bone Marrow Transplant. 2001;28:277–282
  33. Stewart JR, Fajardo LF, Gillette SM, Constine LS. Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31:1205–1211
  34. Adami HO, Trichopoulos D. Obesity and mortality from cancer. N Engl J Med. 2003;348:1623–1624
  35. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625–1638
  36. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst. 2001;93:618–629
  37. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer. 2002;2:124–132
  38. Bhatia S, Meadows AT, Robison LL. Second cancers after pediatric Hodgkin's disease. J Clin Oncol. 1998;16:2570–2572
  39. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;34:745–751
  40. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME, Ruccione K, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol. 2001;19:3163–3172
  41. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey 1988-94. DHHS publication no. (PHS) 94-1308. Available at: http://www.cdc.gov/nchs/data/series/sr_01/sr01_032.pdf. Accessed March 25, 2004.
  42. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics. Analytic and Reporting Guidelines: The Third National Health and Nutrition Examination Survey, NHANES III (1988-94). Available at: http://www.cdc.gov/nchs/data/nhanes/nhanes3/cdrom/nchs/manuals/nh3guide.pdf. Accessed March 25, 2004.
  43. US Code Collection. 42 USC, Chapter 6A, Subchapter II, Part A, Section 242k. Available at: http://uscode.house.gov. Accessed March 25, 2004.
  44. US Code Collection. 5 USC, Part I, Chapter 5, Subchapter II, Section 552a. Available at: http://uscode.house.gov. Accessed March 25, 2004.
  45. Rothman KJ, Greenland S. Introduction to categorical statistics. In: Modern Epidemiology. 2nd ed.. Philadelphia: Lippincott, Williams & Wilkins; 1998;p. 231–252
  46. Oakes JM, Rossi PH. The measurement of SES in health research: Current practice and steps toward a new approach. Soc Sci Med. 2003;56:769–784
  47. Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley & Sons; 1981;24–29
  48. McDowell A, Pitblado J. From the help desk: It's all about the sampling. The Stata Journal. 2002;2:190–201
  49. Korn EL, Graubard BI. Analysis of Health Surveys. New York: John Wiley & Sons; 1999;
  50. Bray GA. Risks of obesity. Prim Care. 2003;30:281–299
  51. Abu-Abid S, Szold A, Klausner J. Obesity and cancer. J Med. 2002;33:73–86

PII: S1047-2797(04)00238-8

doi: 10.1016/j.annepidem.2004.07.092

Annals of Epidemiology
Volume 15, Issue 3 , Pages 202-206 , March 2005

Article Tools

* Image Usage & Resolution